Cargando…

Exploring the Chemical Space of Benzothiazole-Based DNA Gyrase B Inhibitors

[Image: see text] We designed and synthesized a series of inhibitors of the bacterial enzymes DNA gyrase and DNA topoisomerase IV, based on our recently published benzothiazole-based inhibitor bearing an oxalyl moiety. To improve the antibacterial activity and retain potent enzymatic activity, we sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Skok, Žiga, Barančoková, Michaela, Benek, Ondřej, Cruz, Cristina Durante, Tammela, Päivi, Tomašič, Tihomir, Zidar, Nace, Mašič, Lucija Peterlin, Zega, Anamarija, Stevenson, Clare E. M., Mundy, Julia E. A., Lawson, David M., Maxwell, Anthony, Kikelj, Danijel, Ilaš, Janez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734788/
https://www.ncbi.nlm.nih.gov/pubmed/33329764
http://dx.doi.org/10.1021/acsmedchemlett.0c00416
Descripción
Sumario:[Image: see text] We designed and synthesized a series of inhibitors of the bacterial enzymes DNA gyrase and DNA topoisomerase IV, based on our recently published benzothiazole-based inhibitor bearing an oxalyl moiety. To improve the antibacterial activity and retain potent enzymatic activity, we systematically explored the chemical space. Several strategies of modification were followed: varying substituents on the pyrrole carboxamide moiety, alteration of the central scaffold, including variation of substitution position and, most importantly, modification of the oxalyl moiety. Compounds with acidic, basic, and neutral properties were synthesized. To understand the mechanism of action and binding mode, we have obtained a crystal structure of compound 16a, bearing a primary amino group, in complex with the N-terminal domain of E. coli gyrase B (24 kDa) (PDB: 6YD9). Compound 15a, with a low molecular weight of 383 Da, potent inhibitory activity on E. coli gyrase (IC(50) = 9.5 nM), potent antibacterial activity on E. faecalis (MIC = 3.13 μM), and efflux impaired E. coli strain (MIC = 0.78 μM), is an important contribution for the development of novel gyrase and topoisomerase IV inhibitors in Gram-negative bacteria.